XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.24.3

Equity Plans and Stock-Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract] |
Equity Plans and Stock-Based Compensation | Equity Plans and Stock-Based Compensation Equity Plans In January 2021, we adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (“2021 Inducement Plan”), pursuant to which we reserved 1,500,000 shares of common stock for issuance under the plan to be used exclusively for grants of awards to individuals who were not previously our employees or directors. In June 2021, we amended the 2021 Inducement Plan (“Amended 2021 Inducement Plan”) to increase the number of shares of common stock reserved under the 2021 Inducement Plan to 3,250,000. The Amended 2021 Inducement Plan was terminated effective as of April 3, 2022 and, therefore, there are no shares of our common stock available for grant. In May 2024, our stockholders approved the amendment and restatement of our 2018 Equity Incentive Plan (the “Amended 2018 EIP”) to, among other things, increase the authorized number of shares of common stock by 11,400,000. The maximum number of shares of common stock that may be issued under the Amended 2018 EIP, will not exceed 41,440,250 shares of common stock. As of September 30, 2024, the Amended 2018 EIP and the Amended and Restated 2014 Employee Stock Purchase Plan are our active plans (the "Plans"). The Amended 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the Amended 2018 EIP have a term of seven years unless earlier terminated by the Board of Directors. As of September 30, 2024, there were 14,308,992 shares of common stock reserved for issuance under the Amended 2018 EIP. Under our Amended 2018 EIP, we may grant stock options, restricted stock units ("RSUs"), performance-based awards, and other awards that are settled in shares of our common stock. Our equity awards generally vest over a three-year period contingent upon continuous service and unless exercised, expire seven or ten years from the date of grant (or earlier upon termination of continuous service). Activity under our Plans is set forth below: Stock Options The following table summarizes the activity of stock options for the nine months ended September 30, 2024:
| Shares Underlying Outstanding Options (in thousands) |  | Weighted- Average Exercise Price Per Share |  | Weighted- Average Remaining Contractual Term (years) |  | Aggregate Intrinsic Value (in thousands)
Balance as of December 31, 2023 | 10,120 |  | $ | 10.78 |  |  | 4.18 |  | $ | 37,388 |
Options granted | 1,710 |  | 12.37 |  |  |  |  |
Options exercised | (537) |  | 7.76 |  |  |  |  |
Options cancelled: |  |  |  |  |  |  |
Options forfeited (unvested) | (22) |  | 11.56 |  |  |  |  |
Options expired (vested) | (144) |  | 14.63 |  |  |  |  |
Balance as of September 30, 2024 | 11,127 |  | $ | 11.12 |  |  | 3.98 |  | $ | 13,791 |
Vested and expected to vest as of September 30, 2024 | 10,939 |  | $ | 11.10 |  |  | 3.95 |  | $ | 13,788 |
Exercisable as of September 30, 2024 | 8,268 |  | $ | 10.79 |  |  | 3.32 |  | $ | 13,693 |
Restricted Stock Units The following table summarizes the activity of RSUs for the nine months ended September 30, 2024:
| Number of Shares (in thousands) |  | Weighted-Average Grant-Date Fair Value Per Share
Non-vested as of December 31, 2023 | 4,445 |  | $ | 11.57 |
Granted | 3,139 |  | 12.42 |
Vested (1) | (1,815) |  | 11.14 |
Forfeited | (257) |  | 12.38 |
Non-vested as of September 30, 2024 | 5,512 |  | $ | 12.16 |
(1)Inclusive of approximately 699,684 RSUs for the nine months ended September 30, 2024, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital. Market-based Performance Stock Units We granted market-based performance restricted stock units (“PSUs”) to certain executives. These PSUs vest upon a specified market condition. The summary of PSU activities for the nine months ended September 30, 2024 is as follows:
| Number of Shares (in thousands) |  | Weighted-Average Grant-Date Fair Value Per Share
Non-vested as of December 31, 2023 | 557 |  | $ | 15.95 |
Granted | 558 |  | 17.23 |
Non-vested as of September 30, 2024 | 1,115 |  | $ | 16.59 |
Performance-based Options As of September 30, 2024, approximately 36,000 shares underlying performance-based options were outstanding. Significant Assumptions in Estimating Option Fair Value The fair value of each time-based option is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each RSU is determined at the date of grant using our closing stock price. The fair value of each PSU is estimated using the Monte Carlo simulation method on the date of grant. The weighted-average assumptions used in the calculations of these fair value measurements are as follows:
| Stock Options |  | Stock Options |  | Market-Based Performance Stock Units
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023 |  | 2024 |  | 2023
Weighted-average fair value per share | $ | 6.66 |  |  | $ | 8.61 |  |  | $ | 7.82 |  |  | $ | 7.30 |  |  | $ | 17.23 |  |  | $ | 18.25 |
Risk-free interest rate | 3.8 | % |  | 4.2 | % |  | 4.2 | % |  | 4.0 | % |  | 4.3 | % |  | 4.3 | %
Expected life (in years) | 4.5 |  | 4.5 |  | 4.5 |  | 4.5 |  | 2.9 |  | 2.9
Volatility | 0.8 |  | 0.8 |  | 0.8 |  | 0.8 |  | 0.6 |  | 0.9
Stock-based Compensation Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. We have also granted performance-based equity awards to certain of our employees. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable. The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our condensed consolidated statements of operations, and amounts capitalized to our inventories (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Research and development | $ | 3,135 |  |  | $ | 2,339 |  |  | $ | 8,681 |  |  | $ | 6,752 |
Selling, general and administrative | 8,703 |  |  | 7,320 |  |  | 26,878 |  |  | 21,353 |
Cost of sales - product | 397 |  |  | 369 |  |  | 1,505 |  |  | 1,463 |
Inventories | 848 |  |  | 659 |  |  | 2,551 |  |  | 1,715 |
Total | $ | 13,083 |  |  | $ | 10,687 |  |  | $ | 39,615 |  |  | $ | 31,283 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration